This polymorphism probably triggers NAFLD and CAD's pathogenesis in type 2 diabetic patients by altering the PGC-1α interaction with other transcription factors and affecting oxidative stress and lipid metabolism [6, 70]. The gene discussed is PPARGC1A; the disease is metabolic dysfunction-associated steatotic liver disease.